<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02186600</url>
  </required_header>
  <id_info>
    <org_study_id>378-14</org_study_id>
    <nct_id>NCT02186600</nct_id>
  </id_info>
  <brief_title>Heartland Osteoporosis Prevention Study</brief_title>
  <acronym>HOPS</acronym>
  <official_title>Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nancy L. Waltman, BSN MSN PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Creighton University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the best way to prevent bone loss in the first years
      after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take
      calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication
      &quot;risedronate&quot;; or 3) who take calcium and vitamin D plus participate in bone-loading
      exercises. Our central hypothesis is that improvements in bone health will be greater in
      women randomized to bone-loading exercises with calcium and vitamin D compared to women who
      take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial (RCT) will compare changes after 12 months in bone
      structure, bone mineral density (BMD), and bone turnover in women with low bone mass who are
      within 5 years of menopause. Women will be randomized to one control and 2 treatment groups
      (n =103 per group): 1) calcium + vitamin D (CaD) alone (Control); 2) Bisphosphonate (BP) plus
      optimal CaD (Risedronate); and 3) a bone loading exercise program plus optimal CaD
      (Exercise). Our central hypothesis is that improvements in bone health will be greater in
      subjects randomized to the exercise group compared to subjects in either the control or
      risedronate groups. Specific Aims: Aims 1, 2, and 3 are to compare control, risedronate, and
      exercise group subjects on changes in bone structure at the tibia and hip (measured by pQCT
      and Hip Structural Analysis) (Aim 1) ; on changes in BMD at the total hip, femoral neck, and
      spine (Aim 2); and on changes in serum markers of bone formation and resorption (Aim 3). In
      addition, Aim 4 will explore relationships between adherence to exercise (% sessions
      attended) or adherence to risedronate (% pills taken) and changes in bone structure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone structure at hip and tibia based on randomization to Control, Risedronate, or Exercise group.</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Bone structure will be measured at the hip using Hip Structural Analysis (HSA) software and DXA testing. Bone structure will be measured at the 4% and 66% tibial sites using peripheral quantitative computed tomography (pQCT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density (BMD) at hip and spine based on randomization to Control, Risedronate, or Exercise group.</measure>
    <time_frame>Baseline,6, and 12 months</time_frame>
    <description>Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the hip and spine using Dual Energy X-ray Absorptiometry (DXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum measures of bone resorption (Serum NTx) and bone formation (AlkphaseB) based on randomization to Control, Risedronate, or Exercise group.</measure>
    <time_frame>Baseline, 6, 12 months</time_frame>
    <description>Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx and formation by AlkphaseB</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">309</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have ~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the risedronate group will take 35 mg of the bisphosphonate &quot;risedronate&quot; weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.</description>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Actonel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Bone-loading exercises</intervention_name>
    <description>Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are in their first 5 years of menopause

          -  Have a T score between -1 and -2.49 at the femoral neck, total hip, or L1-L4 spine

          -  Be 19 years of age or older

          -  Have their health care provider's permission to enroll in the study.

        Exclusion Criteria:

          -  Have osteoporosis

          -  Have a 10 yr probability of hip fracture &gt;3% or major fracture &gt;20% based on results
             of the fracture risk assessment (FRAX) tool

          -  Currently take bisphosphonates, estrogen replacement therapy, glucocorticosteroids, or
             other drugs affecting bone

          -  Currently participate in a resistance training or high impact weight bearing exercise
             program three or more times weekly

          -  Weigh &gt;300 lbs

          -  Have abnormal results for the following laboratory tests: serum 25(OH)D; serum
             creatinine; serum calcium; parathyroid hormone (PTH); thyroid stimulating hormone
             (TSH).

          -  Have Paget's disease, heart disease, uncontrolled hypertension, renal disease, or
             other concomitant conditions that prohibit participation in exercises, risedronate
             therapy, or use of CaD supplements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy L Waltman, PhD, APRN-NP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Bilek, PT, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy L Waltman, PhD, APRN-NP</last_name>
    <phone>402-472-7354</phone>
    <email>nwaltman@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Bilek, PT, PhD</last_name>
    <phone>402-559-6923</phone>
    <email>lbilek@unmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-4420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy L Waltman, PhD, APRN-NP</last_name>
      <phone>402-472-7354</phone>
      <email>nwaltman@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Bilek, PT, PhD</last_name>
      <phone>402-559-6597</phone>
      <email>lbilek@unmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-Term Alendronate Use Not without Consequences? Int J Rheumatol. 2009;2009:253432. doi: 10.1155/2009/253432. Epub 2010 Jan 27.</citation>
    <PMID>20148064</PMID>
  </reference>
  <reference>
    <citation>Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2009 Jun;24(6):1132-4. doi: 10.1359/jbmr.081253.</citation>
    <PMID>19113923</PMID>
  </reference>
  <reference>
    <citation>Caulfield MP, Reitz RE. Biochemical markers of bone turnover and their utility in osteoporosis. MLO Med Lab Obs. 2004 Apr;36(4):34-7.</citation>
    <PMID>15119056</PMID>
  </reference>
  <reference>
    <citation>Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18-28. Review. Erratum in: Am J Clin Nutr. 2006 Nov;84(5):1253. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. Am J Clin Nutr. 2007 Sep;86(3):809. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.</citation>
    <PMID>16825677</PMID>
  </reference>
  <reference>
    <citation>Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005 May 11;293(18):2257-64. Review.</citation>
    <PMID>15886381</PMID>
  </reference>
  <reference>
    <citation>Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005 Mar;90(3):1897-9.</citation>
    <PMID>15758064</PMID>
  </reference>
  <reference>
    <citation>Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006 Jan;61(1):31-3.</citation>
    <PMID>16405362</PMID>
  </reference>
  <reference>
    <citation>Hamdy RC, Petak SM, Lenchik L; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. Which central dual X-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom. 2002;5 Suppl:S11-8. Review.</citation>
    <PMID>12464707</PMID>
  </reference>
  <reference>
    <citation>van der Linden JC, Weinans H. Effects of microarchitecture on bone strength. Curr Osteoporos Rep. 2007 Jun;5(2):56-61. Review.</citation>
    <PMID>17521506</PMID>
  </reference>
  <reference>
    <citation>Akhter MP, Lappe JM, Davies KM, Recker RR. Transmenopausal changes in the trabecular bone structure. Bone. 2007 Jul;41(1):111-6. Epub 2007 Apr 10.</citation>
    <PMID>17499038</PMID>
  </reference>
  <reference>
    <citation>Beck TJ. Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep. 2007 Jun;5(2):49-55. Review.</citation>
    <PMID>17521505</PMID>
  </reference>
  <reference>
    <citation>Twiss JJ, Waltman NL, Berg K, Ott CD, Gross GJ, Lindsey AM. An exercise intervention for breast cancer survivors with bone loss. J Nurs Scholarsh. 2009 Mar;41(1):20-7. doi: 10.1111/j.1547-5069.2009.01247.x.</citation>
    <PMID>19335674</PMID>
  </reference>
  <reference>
    <citation>Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010 Jan-Feb;17(1):25-54; quiz 55-6. doi: 10.1097/gme.0b013e3181c617e6.</citation>
    <PMID>20061894</PMID>
  </reference>
  <reference>
    <citation>Lappe JM, Davies KM, Travers-Gustafson D, Heaney RP. Vitamin D status in a rural postmenopausal female population. J Am Coll Nutr. 2006 Oct;25(5):395-402.</citation>
    <PMID>17031008</PMID>
  </reference>
  <reference>
    <citation>Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004 Apr;34(4):736-46.</citation>
    <PMID>15050906</PMID>
  </reference>
  <reference>
    <citation>Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV; Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011 Sep;22(9):2395-411. doi: 10.1007/s00198-011-1713-z. Epub 2011 Jul 21. Review.</citation>
    <PMID>21779818</PMID>
  </reference>
  <reference>
    <citation>Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP; American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011 Jul;43(7):1334-59. doi: 10.1249/MSS.0b013e318213fefb.</citation>
    <PMID>21694556</PMID>
  </reference>
  <reference>
    <citation>Maddalozzo GF, Widrick JJ, Cardinal BJ, Winters-Stone KM, Hoffman MA, Snow CM. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women. Bone. 2007 May;40(5):1244-51. Epub 2006 Dec 29.</citation>
    <PMID>17291843</PMID>
  </reference>
  <reference>
    <citation>Ashe MC, Gorman E, Khan KM, Brasher PM, Cooper DM, McKay HA, Liu-Ambrose T. Does frequency of resistance training affect tibial cortical bone density in older women? A randomized controlled trial. Osteoporos Int. 2013 Feb;24(2):623-32. doi: 10.1007/s00198-012-2000-3. Epub 2012 May 12.</citation>
    <PMID>22581292</PMID>
  </reference>
  <results_reference>
    <citation>Bocalini DS, Serra AJ, dos Santos L, Murad N, Levy RF. Strength training preserves the bone mineral density of postmenopausal women without hormone replacement therapy. J Aging Health. 2009 Jun;21(3):519-27. doi: 10.1177/0898264309332839. Epub 2009 Feb 27.</citation>
    <PMID>19252142</PMID>
  </results_reference>
  <results_reference>
    <citation>Uusi-Rasi K, Kannus P, Cheng S, Sievänen H, Pasanen M, Heinonen A, Nenonen A, Halleen J, Fuerst T, Genant H, Vuori I. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone. 2003 Jul;33(1):132-43.</citation>
    <PMID>12919708</PMID>
  </results_reference>
  <results_reference>
    <citation>Bergström I, Landgren B, Brinck J, Freyschuss B. Physical training preserves bone mineral density in postmenopausal women with forearm fractures and low bone mineral density. Osteoporos Int. 2008 Feb;19(2):177-83. Epub 2007 Sep 1.</citation>
    <PMID>17768587</PMID>
  </results_reference>
  <results_reference>
    <citation>Dane C, Dane B, Cetin A, Erginbas M. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. Gynecol Endocrinol. 2008 Apr;24(4):207-13. doi: 10.1080/09513590801895617.</citation>
    <PMID>18382907</PMID>
  </results_reference>
  <results_reference>
    <citation>Cussler EC, Going SB, Houtkooper LB, Stanford VA, Blew RM, Flint-Wagner HG, Metcalfe LL, Choi JE, Lohman TG. Exercise frequency and calcium intake predict 4-year bone changes in postmenopausal women. Osteoporos Int. 2005 Dec;16(12):2129-41. Epub 2005 Nov 10.</citation>
    <PMID>16283062</PMID>
  </results_reference>
  <results_reference>
    <citation>Elders PJ, Netelenbos JC, Lips P, van Ginkel FC, Khoe E, Leeuwenkamp OR, Hackeng WH, van der Stelt PF. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. J Clin Endocrinol Metab. 1991 Sep;73(3):533-40.</citation>
    <PMID>1874931</PMID>
  </results_reference>
  <results_reference>
    <citation>Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007 Sep;29(9):1937-49.</citation>
    <PMID>18035193</PMID>
  </results_reference>
  <results_reference>
    <citation>Vainionpää A, Korpelainen R, Sievänen H, Vihriälä E, Leppäluoto J, Jämsä T. Effect of impact exercise and its intensity on bone geometry at weight-bearing tibia and femur. Bone. 2007 Mar;40(3):604-11. Epub 2006 Nov 30.</citation>
    <PMID>17140871</PMID>
  </results_reference>
  <results_reference>
    <citation>Waltman NL, Twiss JJ, Ott CD, Gross GJ, Lindsey AM, Moore TE, Berg K, Kupzyk K. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporos Int. 2010 Aug;21(8):1361-9. doi: 10.1007/s00198-009-1083-y. Epub 2009 Oct 3.</citation>
    <PMID>19802506</PMID>
  </results_reference>
  <results_reference>
    <citation>Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000 May;85(5):1895-900.</citation>
    <PMID>10843171</PMID>
  </results_reference>
  <results_reference>
    <citation>Going S, Lohman T, Houtkooper L, Metcalfe L, Flint-Wagner H, Blew R, Stanford V, Cussler E, Martin J, Teixeira P, Harris M, Milliken L, Figueroa-Galvez A, Weber J. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. Osteoporos Int. 2003 Aug;14(8):637-43. Epub 2003 Jul 3.</citation>
    <PMID>12844212</PMID>
  </results_reference>
  <results_reference>
    <citation>Kemmler W, Engelke K, Lauber D, Weineck J, Hensen J, Kalender WA. Exercise effects on fitness and bone mineral density in early postmenopausal women: 1-year EFOPS results. Med Sci Sports Exerc. 2002 Dec;34(12):2115-23.</citation>
    <PMID>12471325</PMID>
  </results_reference>
  <results_reference>
    <citation>Vainionpää A, Korpelainen R, Väänänen HK, Haapalahti J, Jämsä T, Leppäluoto J. Effect of impact exercise on bone metabolism. Osteoporos Int. 2009 Oct;20(10):1725-33. doi: 10.1007/s00198-009-0881-6. Epub 2009 Mar 5.</citation>
    <PMID>19262975</PMID>
  </results_reference>
  <results_reference>
    <citation>Klentrou P, Slack J, Roy B, Ladouceur M. Effects of exercise training with weighted vests on bone turnover and isokinetic strength in postmenopausal women. J Aging Phys Act. 2007 Jul;15(3):287-99.</citation>
    <PMID>17724395</PMID>
  </results_reference>
  <results_reference>
    <citation>Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, Chlebowski RT, Manson JE, Van Horn L, Vitolins MZ, Datta M, LeBlanc ES, Cauley JA, Rossouw JE. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int. 2013 Feb;24(2):567-80. doi: 10.1007/s00198-012-2224-2. Epub 2012 Dec 4.</citation>
    <PMID>23208074</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Nancy L. Waltman, BSN MSN PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Low bone mass</keyword>
  <keyword>Post-menopausal women</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Bone structure</keyword>
  <keyword>Bone turnover</keyword>
  <keyword>Bone-loading exercises</keyword>
  <keyword>calcium and vitamin D</keyword>
  <keyword>risedronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

